ZILRETTA (triamcinolone acetonide extended-release injectable suspension)

Product · Pharmaceutical / drug by Viatris

Non-opioid extended-release therapy for osteoarthritis knee pain.

ZILRETTA is an extended-release injectable suspension of triamcinolone acetonide for the management of osteoarthritis knee pain. It offers a non-opioid alternative for sustained pain relief in the U.S. market.

Languages
English
Indications
Management of osteoarthritis knee pain
Forms and strengths
Extended-release injectable suspension
Active Ingredient
Triamcinolone acetonide
Formulation
Extended-release injectable suspension
Primary Indication
Osteoarthritis knee pain
Therapeutic Class
Non-opioid pain therapy
  • Indicated for osteoarthritis knee pain management
  • Non-opioid pain management therapy
  • Extended-release injectable suspension formulation
  • Patent-protected medicine marketed in the U.S.

Overview

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an innovative medicine indicated for the management of osteoarthritis knee pain. It serves as a non-opioid treatment option for patients and healthcare providers seeking alternatives to traditional pain management therapies. The product utilizes extended-release technology to deliver triamcinolone acetonide, providing sustained relief for chronic knee pain. It is a patent-protected, high-margin medicine currently marketed in the United States. Viatris plans to leverage its global infrastructure and medical affairs capabilities to expand the product's reach into international markets.

Clinical Applications

  • Osteoarthritis Knee Pain Management: ZILRETTA is a triamcinolone acetonide extended-release injectable suspension specifically indicated for the management of osteoarthritis knee pain.
  • Non-Opioid Therapy: The product provides a non-opioid treatment option for patients and healthcare providers seeking alternatives in pain management.
  • Extended-Release Technology: ZILRETTA utilizes extended-release technology to provide sustained relief for patients suffering from chronic knee pain.

Market and Availability

  • U.S. Market Presence: The product is a patent-protected medicine currently marketed in the United States.
  • Global Expansion Plans: Viatris intends to expand the reach of ZILRETTA across selected markets within its international infrastructure.

Use cases

  • Healthcare providers administer ZILRETTA to patients suffering from osteoarthritis knee pain to provide non-opioid relief.
  • Patients seeking long-term management of chronic knee pain use this extended-release injectable suspension for sustained treatment.

Specifications

Indications
Management of osteoarthritis knee pain
Forms and strengths
Extended-release injectable suspension
Availability
Marketed in the United States with plans for international expansion
Active Ingredient
Triamcinolone acetonide
Formulation
Extended-release injectable suspension
Primary Indication
Osteoarthritis knee pain
Therapeutic Class
Non-opioid pain therapy

Added by AntSpace from public sources (newsroom.viatris.com).

Related

More products by Viatris